Form 8-K - Current report:
SEC Accession No. 0001723128-25-000018
Filing Date
2025-05-02
Accepted
2025-05-02 06:18:24
Documents
15
Period of Report
2025-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20250502.htm   iXBRL 8-K 29288
2 EX-99.1 amrx-q12025ex991.htm EX-99.1 346677
6 amneal.jpg GRAPHIC 2670
  Complete submission text file 0001723128-25-000018.txt   533005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20250502.xsd EX-101.SCH 1876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20250502_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20250502_pre.xml EX-101.PRE 12599
18 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20250502_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 25905396
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)